Work

Quality of life (QOL) analysis from E3805, chemohormonal androgen ablation randomized trial (CHAARTED) in prostate cancer (PrCa).

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.2_suppl.286

Authors: Linda J. Patrick-Miller, Yu-Hui Chen, Michael Anthony Carducci, David Cella, Robert S. DiPaola, Benjamin Adam Gartrell, David Frazier Jarrard, Glenn Liu, Alicia Katherine Morgans, Yu-Ning Wong, Christopher Sweeney

Institutions: University of Chicago Medical Center, Dana-Farber Cancer Institute, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Northwestern University, Rutgers Cancer Institute, Montefiore Medical Center, University of Wisconsin–Madison, UW Health University Hospital, University of Wisconsin Carbone Cancer Center, Vanderbilt University Medical Center, Fox Chase Cancer Center, Temple University Health System

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2591308365

Cites:

Cited by: 10

Related to: 10